Metabolomics data and the biomarker qualification process

Metabolomics

Volumn 8, Issue 1, 2012, Pages 2-7

  Beger, Richard D ^a   Colatsky, Thomas ^b  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Biomarkers; Drug safety; Metabolomics; Metabonomics; Personalized medicine

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; CREATININE; GLUCOSE;

CLINICAL MEDICINE; DRUG DEVELOPMENT; EVIDENCE BASED PRACTICE; METABOLOMICS; PERSONALIZED MEDICINE; QUALITY CONTROL; REVIEW; VALIDATION PROCESS; VOLUNTARY REPORTING;

EID: 84855872860     PISSN: 15733882     EISSN: 15733890     Source Type: Journal    
DOI: 10.1007/s11306-011-0342-z     Document Type: Review

References (63)

1. Aranibar, N., Vassallo, J. D., et al. (2010). Identification of 1- and 3-methylhistidine as biomarkers of skeletal muscle toxicity by NMR-based metabolic profiling. Analytical Biochemistry, 410, 84-91.
2. Assfalg, M., Bertini, I., et al. (2008). Evidence of different metabolic phenotypes in humans. Proceedings of National Academy of Science USA, 105(5), 1420-1424.
3. Beger, R. D., Holland, R. D., et al. (2008). Metabonomics of acute kidney injury in children after cardiac surgery. Pediatric Nephrology, 23, 977-984.
4. Beger, R. D., Sun, J., et al. (2010). Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity. Toxicology and Applied Pharmacology, 243, 154-166.
5. Boros, L. G., Lerner, M. R., et al. (2005). [1, 2-13C2]-d-Glucose profiles of the serum, liver, pancreas, and DMBA-induced pancreatic tumors of rats. Pancreas, 31, 337-343.
6. Boudonck, K. J., Mitchell, M. W., et al. (2009). Discovery of metabolomics biomarkers for early detection of nephrotoxicity. Toxicologic Pathology, 37, 280-292.
7. Chen, C., Krausz, K. W., et al. (2009). Serum metabolomics reveals irreversible inhibition of fatty acid β-oxidation through the suppression of PPARα activation as a contributing mechanism of Acetaminophen-induced hepatotoxicity. Chemical Research in Toxicology, 22, 699-707.
8. Chung, Y. L., & Griffiths, J. R. (2007). Using metabolomics to monitor anticancer drugs. Ernst Schering Foundation Symposium Proceedings, 4, 55-78.
9. Clayton, T. A., Lindon, J. C., et al. (2006). Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature, 440, 1073-1077.
10. Colatsky, T. J., & Sumner, S. (2003). Metabolic profiling and biomarker discovery. Current Opinion in Investigational Drugs, 4, 262-263.
11. Dong, J., Cai, X., et al. (2010). Lysophosphatidylcholine profiling of plasma: discrimination of isomers and discovery of lung cancer biomarkers. Metabolomics, 6, 478-488.
12. Ebbels, T. M., Keun, H. C., et al. (2007). Prediction and classification of drug toxicity using probabilistic modeling of temporal metabolic data: the consortium on metabonomic toxicology screening approach. Journal of Proteome Research, 6, 4407-4422.
13. Fan, T. W., Lane, A. N., et al. (2009). Altered regulation and metabolic pathways in human lung cancer discerned by 13C isotope-resolved metabolomics (SIRM). Molecular Cancer, 8, 41.
14. Ferrara, C. T., Wang, P., et al. (2008). Genetic networks of liver metabolism revealed by integration of metabolic and transcriptional profiling. PLos Genetics, 4, e1000034.
15. Fiehn, O. (2002). Metabolomics-the link between genotypes and phenotypes. Plant Molecular Biology, 48, 155-171.
16. Fiehn, O., Robertson, D., et al. (2007). The metabolomics standards initiative (MSI). Metabolomics, 3, 175-178.
17. Gall, W. E., Beebe, B., et al. (2010). Alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS ONE, 5, e10883.
18. Gieger, C., Geislinger, L., et al. (2008). Genetics meets metabolomics: A genome-wide association study of metabolite profiles in human serum. PLos Genetics, 4, e1000282.
19. Goodacre, R., Broadhurst, D., et al. (2007). Proposed minimum reporting standards for data analysis in metabolomics. Metabolomics, 3, 231-241.
20. Goodsaid, F. M., Amur, S., et al. (2010). Voluntary exploratory data submissions to the US FDA and the EMA: Experience and impact. Nature Reviews Drug Discovery, 9, 435-450.
21. Goodsaid, F. M., & Frueh, F. W. (2007). Biomarker qualification pilot process at the US Food and Drug Administration. AAPS Journal, 9(1), E105-E108.
22. Goodsaid, F. M., Frueh, F. W., et al. (2008). Strategic paths for biomarker qualification. Toxicology, 245, 219-223.
23. Griffin, J. L., Nicholls, A. W., et al. (2007). Standard reporting requirements for biological samples in metabolomics experiments: mammalian/in vivo experiments. Metabolomics, 3, 179-188.
24. Harrigan, G. G., & Goodacre, R. (Eds.). (2003). Metabolic profiling: Its role in biomarker discovery and gene function analysis. Boston: Kluwer Academic Publishers.
25. Ji, Y., Hebbring, S., et al. (2010). Glycine and a glycine dehydrogenase (GLDC) SNP as Citalopram/Escitalopram response biomarkers in depression: Pharmacometabolomics-informed pharmacogenomics. Clinical Pharmacology and Therapeutics, 89, 97-104.
26. Kaddurah-Daouk, R., Kristal, B. S., et al. (2008). Metabolomics: A global biochemical approach to drug response and disease. Annual Review of Pharmacology and Toxciology, 48, 653-683.
27. Kitteringham, N. R., Jenkins, R. E., et al. (2009). Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics. Journal of Chromatography B, 877, 1229-1239.
28. Lane, A. N., Fan, T. W., et al. (2008). Stable isotope-assisted metabolomics in cancer research. IUBMB Life, 60, 124-129.
29. Liu, H.-H., Lu, P., et al. (2010). An integrative genomic analysis identifies Bhmt2 as a diet-dependent genetic factor protecting against acetaminophen-induced liver toxicity. Genome Research, 20, 28-35.
30. Maguire, G., Lee, P., et al. (2006). SiDMAP: A metabolomics approach to assess the effects of drug candidates on the dynamic properties of biochemical pathways. Expert Opinion in Drug Discovery, 1, 351-359.
31. Martin, F.-P., Wang, Y., et al. (2008). Probiotic modulation of symbiotic gut microflora-host metabolic interactions in a humanized microbiome mouse model. Molecular Systems Biology, 4, 157.
32. Matheis, K., Laurie, D., et al. (2011). A generic operational strategy to qualify translational safety biomarkers. Drug Discovery Today, 16, 600-608.
33. Mattes, W. B., Walker, E. G., et al. (2010). Research at the interface of industry, academia and regulatory science. Nature Biotechnology, 28, 432-433.
34. Mayr, M., Mayr, U., et al. (2004). Vascular proteomics: linking proteomic and metabolomic changes. Proteomics, 4, 3751-3761.
35. Morris, M., & Watkins, S. M. (2005). Focused metabolomic profiling in the drug development process: advances from lipid profiling. Current Opinion in Chemical Biology, 9, 407-412.
36. Mortishire-Smith, R. J., Skiles, G. L., et al. (2004). Use of metabonomics to identify impaired fatty acid metabolism as the mechanism of a drug-induced toxicity. Chemical Research in Toxicology, 17, 165-173.
37. Morvan, D., & Demidem, A. (2007). Metabolomics by proton nuclear magnetic resonance spectroscopy of the response to chloroethylnitrosurea reveals drug efficacy and tumor adaptive metabolic pathways. Cancer Research, 67, 2150-2159.
38. Newgard, C. B., An, J., et al. (2009). A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metabolism, 9, 311-326.
39. Nicholson, J. K., Holmes, E., et al. (2005). Gut microbes, mammalian metabolism and personalized healthcare. Nature Reviews Microbiology, 3, 2-8.
40. Nicholson, J. K., Lindon, J. C., et al. (1999). 'Metabonomics': Understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica, 29, 1181-1189.
41. Nishiumi, S., Shinohara, M., et al. (2010). Serum metabolomics as a novel diagnostic approach for pancreatic cancer. Metabolomics, 6, 518-528.
42. O'Connell, T. M., & Watkins, P. B. (2010). The application of metabolomics to predict drug-induced liver injury. Clinical Pharmacology and Therapeutics, 88, 394-399.
43. Oresic, M. (2010). Systems biology strategy to study lipotoxicity and the metabolic syndrome. Biochimica et Biophysica Acta, 1801, 235-239.
44. Quinones, M. P., & Kaddurah-Daouk, R. (2009). Metabolomics tools for identifying biomarkers for neuropsychiatric diseases. Neurobiology of Disease, 35, 165-176.
45. Robertson, D. G. (2005). Metabonomics in toxicology: A review. Toxicological Sciences, 85, 809-822.
46. Robertson, D. G., Watkins, P. B., et al. (2011). Metabolomics in toxicology: Preclinical and clinical applications. Toxicological Sciences, 120, S146-S170.
47. Robosky, L. C., Wells, D. F., et al. (2005). Metabonomic identification of two distinct phenotypes in Sprague-Dawley (Crl: CD(SD)) rats. Toxicological Sciences, 87, 277-284.
48. Schnackenberg, L. K., Chen, M., et al. (2009). Evaluations of the trans-sulfuration pathway in multiple liver toxicity studies. Toxicology and Applied Pharmacology, 235, 25-32.
49. Schnackenberg, L. K., Jones, R. C., et al. (2006). An integrated study of acute effects of valproic acid in the liver using metabonomics, proteomics, and transcriptomics platforms. OMICS, 10, 1-14.
50. Sistare, F. D., Dieterle, F., et al. (2010). Towards consensus practices to qualify safety biomarkers for use in early drug development. Nature Biotechnology, 28, 446-454.
51. Soga, T., Baran, R., et al. (2006). Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption. Journal of Biological Chemistry, 281, 16768-16776.
52. Spratlin, J. L., Serkova, N. J., et al. (2009). Clinical applications of metabolomics in oncology: A review. Clinical Cancer Research, 15, 431-440.
53. Sreekumar, A., Poisson, L. M., et al. (2009). Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature, 457, 910-914.
54. Sugimoto, M., Wong, D. T., et al. (2010). Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast, and pancreatic cancer-specific profiles. Metabolomics, 6, 78-95.
55. Sumner, L. W., Amberg, A., et al. (2007). Proposed minimum reporting standards for chemical analysis. Metabolomics, 3, 211-221.
56. US, Food and Drug Administration. (2006). Guidance for industry Pharmacogenomic data submissions. http://www. fdagov/cder/guidance/6400fnl. pdf. Accessed 1 April 2011.
57. US, Food and Drug Administration. (2010). Guidance for industry: Qualification process for drug development tools. http://www. fda. gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM230597. pdf. Accessed 31 March 2011.
58. Viswanathan, C. T., Bansai, S., et al. (2007). Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharmaceutical Research, 24, 1962-1973.
59. Waters, N. J., Waterfield, C. J., et al. (2006). Integrated metabonomic analysis of bromobenzene-induced hepatotoxicity: novel induction of 5-oxoprolinosis. Journal of Proteome Research, 5, 1448-1459.
60. Watkins, S. M., & German, J. B. (2002). Metabolomics and biochemical profiling in drug discovery and development. Current Opinion in Molecular Therapeutics, 4, 224-228.
61. Wei, R. (2011). Metabolomics and its practical value in pharmaceutical industry. Current Drug Metabolism, 12, 345-358.
62. Wikoff, W. R., Anfora, A. T., et al. (2009). Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proceedings of National Academy of Science USA, 106, 3698-3703.
63. Yi, L. Z., Yuan, D. L., et al. (2008). Plasma fatty acid metabolic profile coupled with uncorrelated linear discriminant analysis to diagnose and biomarker screening of type 2 diabetes and type 2 diabetic coronary heart diseases. Metabolomics, 4, 30-38.